In this week's issue for #EULAR2019: Upadacitinib as monotherapy in patients with active #rheumatoidarthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study https://t.co/hyAKuBPVtJ https://t.co/xSnHZFZtKo

We’re getting closer to something we can use.....RT @sylba2308: New targets in #osteoarthritis #EULAR2019 https://t.co/sBEkeJuPza

Contemporary epidemiology of gout in the UK population.. #EULAR2019 @KeeleUniversity #Gout https://t.co/lcNz84InBL

Interesting politic that may exist between the 2 authoritative bodies on axial vs peripheral SpA #eular2019 https://t.co/Ksc4C3iELj

@_connectedcare @LaurentGrange I am just curious to see their names but really challenging to remember them. https://t.co/TuKQNcfu5m

Gout and associated comorbidities - Edward Roddy @KeeleUniversity #EULAR2019 https://t.co/KC3ITm0FKZ

Multitarget therapy for #Lupus under development 👉🏻 Fenebrutinib @Roche 👉🏻 Evobrutinib @MerckHealthcare 👉🏻 Spleen Kinase Inhibitors @GileadSciences @RigelPharma 👉🏻 Encoding transcription factors @Celgene 👉🏻 JAK/Tyk Inhibitors @PfizerCongress @LillyRheumEU @bmsnews @GSK #EULAR2019 https://t.co/CeUwIQaCx4

Gout management in CKD & allopurinol in the renal function.. - Roddy @KeeleUniversity #EULAR2019 https://t.co/B9TP4jHb4k

Marc de Meulemeester presents finding of #gout survey of 1100 patients across Europe at #EULAR2019. Significant burden of disease: 10% of patients had lost their job/retired due to gout, ability to walk, sleep, mental health & sex lives affected. https://t.co/uAcoChIBhV

Ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic #lupus erythematosus - a between group difference of 29%. Article in @TheLancet https://t.co/kic3xAfHcE #EULAR2019 #LancetRheumatology https://t.co/Wizel4nnSk

Predictors of severe cranial ischemic complications in Giant cell arteritis. 20%GPC patients presented/developed severe vision manifestations and/or ischemic stroke.. age and jaw claudication predicted severe cranial ischemic complications ~ Alojzija Hocevar #eular2019 https://t.co/PSaRfD5kSa